Gileads Biktarvy supports virus suppression and tolerance in Asian HIV patients

Gilead Sciences, Inc. announced results from multiple studies in the Asian population on October 15, 2020 evaluating the safety and effectiveness of switching to Biktarvy, a once-daily tablet with one tablet^® (Bictegravir 50 mg / Emtricitabine 200 mg / Tenofovir alafenamide 25 mg tablets, B / F / TAF) from the baseline regimens at the 2020 AIDS & Co-Infections Conference in the Asia-Pacific region (APACC).

A post-hoc pooled analysis from three studies showed the effectiveness of switching to B / F / TAF from antiretroviral therapy based on an integrase strand transfer inhibitor (INSTI) or a boosted protease inhibitor (PI) with two baselines – Nucleotide reverse transcriptase inhibitor (NRTI) regimens among virologically suppressed Asian adults living with HIV. In the analysis, 100 percent of the 63 Asian adults who switched to B / F / TAF retained virologic suppression (defined as HIV-1 RNA

Similarly, an open, randomized phase 3 study in women with HIV who had been virologically suppressed (HIV-1 RNA

These results further demonstrate the well-established efficacy and safety profile of Biktarvy. No participant in B / F / TAF developed treatment-related resistance. The additional data further define the treatment regimen.

Biktarvy^® (Bictegravir 50 mg / Emtricitabine 200 mg / Tenofovir alafenamide 25 mg; B / F / TAF) is approved in Hong Kong, Singapore, South Korea, Taiwan and Thailand as a single daily tablet (STR) for the treatment of HIV. 1 infection in adults. B / F / TAF is indicated for the treatment of HIV-1 infection in adults with no current or previous evidence of viral resistance to the integrase inhibitor class emtricitabine or tenofovir.